The Hormone Panel for Males can be used as an initial screen to determine if treatment with bioidentical hormone replacement is needed. Once a decision to start therapy is made, many physicians order a more comprehensive panel to establish a comprehensive baseline hormone status as well as for safety monitoring at periodic intervals. Significant deviations from the normal range may require further evaluation by your physician.
Please Note: Female patients ordering this panel will not receive the PSA test due to ordering restrictions.
Information from the Nurses' Health Study indicated that the combination of estrogen and androgen used to treat hypoandrogenism could increase breast cancer risk. However, other studies indicated androgens may decrease breast cancer risk. Follow-up studies on the Women's Health Initiative found women who received estrogen and no progestogen showed a significant decrease in cardiovascular disease (CVD) and breast cancer. This has caused a reconsideration of androgens added to estrogens. Still, the FDA requires demonstration of CVD and breast cancer safety for any product containing androgens or estrogen plus an androgen; that has not been done.